Cartesian Therapeutics, Inc. (RNAC) financial statements and ratios from SEC XBRL: revenue $2.80M (TTM), net margin -4658.6%, revenue growth -92.8% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $2.80M |
| Net Margin | -4658.6% |
| Revenue Growth (YoY) | -92.8% |
| EPS Growth (YoY) | 12.1% |
| FCF Growth (YoY) | 142.3% |
| Price / Sales | 152.93 |
| FCF Yield | -51.5% |
| Altman Z-Score | -4.63 (distress) |
| Sector P/E (Healthcare) | 21.7 |
RNAC overview · RNAC earnings · RNAC KPIs · RNAC investor relations · RNAC ownership · RNAC peers · RNAC filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.